Skip to main content
. 2019 Jan 20;49(4):408–418. doi: 10.1111/apt.15113

Figure 3.

Figure 3

Odds ratios for: (A) clinical response and remission by estimated vedolizumab clearance quartiles at week 6; (B) vedolizumab concentration quartiles at week 6; and (C) estimated vedolizumab trough concentration quartiles at steady state from low (quartile 1) to high (quartile 4). Dashed lines indicate zero